DOCSLIB.ORG

Breast Cancer Screening and Diagnosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Breast Cancer Screening and Diagnosis NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer Screening and Diagnosis Version 1.2019 — May 17, 2019 NCCN.org Continue Version 1.2019, 05/17/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 1.2019 Table of Contents Breast Cancer Screening and Diagnosis Discussion *Therese B. Bevers, MD/Chair Þ Richard Gray, MD ¶ Liane Philpotts, MD ф The University of Texas Mayo Clinic Cancer Center Yale Cancer Center/Smilow Cancer Hospital MD Anderson Cancer Center Randall E. Harris, MD, PhD Þ ≠ Donna Plecha, MD ф *Mark Helvie, MD/Vice-Chair ф Þ The Ohio State University Comprehensive Case Comprehensive Cancer Center/ University of Michigan Cancer Center - James Cancer Hospital University Hospitals Seidman Cancer Rogel Cancer Center and Solove Research Institute Center and Cleveland Clinic Taussig Cancer Institute Ermelinda Bonaccio, MD ф Teresa Helsten, MD † Roswell Park Comprehensive Cancer Center UC San Diego Moores Cancer Center Jennifer K. Plichta, MD, MS ¶ Duke Cancer Institute Kristine E. Calhoun, MD ¶ Linda Hodgkiss, MD ф University of Washington/ St. Jude Children’s Research Hospital/ Mary Lou Smith, JD, MBA ¥ Seattle Cancer Care Alliance The University of Tennessee Health Research Advocacy Network Science Center Melissa Camp, MD ¶ Roberta M. Strigel, MD, MS ф The Sidney Kimmel Comprehensive Tamarya L. Hoyt, MD ф University of Wisconsin Cancer Center at Johns Hopkins Vanderbilt-Ingram Cancer Center Carbone Cancer Center Mary B. Daly, MD, PhD † John G. Huff, MD ф Lusine Tumyan, MD ф Fox Chase Cancer Center Vanderbilt-Ingram Cancer Center City of Hope National Medical Center Constance Dobbins Lehman, MD, PhD ф Maxine S. Jochelson, MD ф Cheryl Williams, MD ф Massachusetts General Hospital Memorial Sloan Kettering Cancer Center Fred & Pamela Buffett Cancer Center Cancer Center Bethany L. Niell, MD, PhD ф Nicole S. Winkler, MD ф William B. Farrar, MD ¶ Moffitt Cancer Center Huntsman Cancer Institute The Ohio State University Comprehensive at the University of Utah Cancer Center - James Cancer Hospital Catherine C. Parker, MD ¶ and Solove Research Institute O'Neal Comprehensive Catherine Young, MD ф Cancer Center at UAB Siteman Cancer Center at Barnes- Judy E. Garber, MD, MPH † Jewish Hospital and Washington Dana-Farber/Brigham and Mark Pearlman, MD Ω ¶ University School of Medicine Women’s Cancer Center University of Michigan Rogel Cancer Center ф Diagnostic/Interventional † Medical oncology radiology ≠Pathology Ω Gynecologic oncology/ ¥ Patient advocacy NCCN Guidelines Panel Disclosures Gynecology ¶ Surgery/Surgical oncology NCCN Continue Þ Internist/Internal medicine, * Discussion Section Writing Mary Anne Bergman including family practice, Committee preventive management Rashmi Kumar, PhD Version 1.2019, 05/17/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 1.2019 Table of Contents Breast Cancer Screening and Diagnosis Discussion NCCN Breast Cancer Screening and Diagnosis Panel Members Clinical Trials: NCCN believes that Summary of the Guidelines Updates the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is Clinical Encounter Including Risk Assessment (BSCR-1) especially encouraged. Average Risk, Screening/Follow-Up (BSCR-1) To find clinical trials online at NCCN Increased Risk, Screening/Follow-Up (BSCR-2) Member Institutions, click here: Symptomatic During Clinical Encounter, Presenting Signs/Symptoms (BSCR-4) nccn.org/clinical_trials/clinicians.aspx. • Palpable Mass, Age ≥30 Years (BSCR-5) NCCN Categories of Evidence and Consensus: All recommendations • Palpable Mass, Age <30 Years (BSCR-11) are category 2A unless otherwise • Nipple Discharge, No Palpable Mass (BSCR-13) indicated. • Asymmetric Thickening/Nodularity (BSCR-14) See NCCN Categories of Evidence • Skin Changes (BSCR-15) and Consensus. Persistent or Severe Breast Pain (BSCR-16) Recommendations for Follow-up of Axillary Mass (BSCR-18) Breast Cancer Presentation in Men (BSCR-19) Mammographic Evaluation (BSCR-20) Breast Screening Considerations (BSCR-A) Risk Factors Used in the Modified Gail Model, Age ≥35 Years (BSCR-B) Assessment Category Definitions (BSCR-C) The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2019. Version 1.2019, 05/17/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 1.2019 Table of Contents Breast Cancer Screening and Diagnosis Discussion Updates in Version 1.2019 of the NCCN Guidelines for Breast Cancer Screening and Diagnosis from Version 3.2018 include: BSCR-1 Footnotes: Increased Risk: • "m" modified: High-quality breast MRIlimitations include having: a need • 2nd bullet modified: Women who have a lifetime risk ≥20% as defined by for requires a dedicated breast coil, the ability to perform access to biopsy models that are largely dependent on family history under MRI guidance, experienced radiologists in breast MRI, and regional • 5th bullet modified: Women with a history of LCIS or ADH/ALH and greater availability. Breast MRI is performed preferably days 7–15 of menstrual than 20% lifetime risk cycle for premenopausal women. MRI should be integrated correlated with other breast imaging modalities. • 6th bullet, 1st sub-bullet modified: Referral to genetic counseloror similarly • "n" is new to the page, Consider whole breast ultrasound for those who trained provider, if not already done qualify but cannot undergo MRI, corresponding to annual breast MRI. (Also Footnotes: for BSCR-3) • " b" modified: Medicare and insurers allow the patient direct access to BSCR-3 . scheduling for screening mammography Increased Risk: • "c" modified: At minimum medical and family history should be obtained • Lower pathway modified: Women with ahistory of LCIS or ADH/ALH and and clinical encounter should encompass ongoing risk assessment, risk greater than 20% lifetime risk reduction counseling, as well as a clinical breast exam by a licensed • 3rd bullet modified: Consider annual breast MRI provider. Refer to the NCCN Guidelines for Breast Cancer Risk Reduction BSCR-4 for a detailed qualitative and quantitative assessment. (Also for BSCR-2, • New pathway off, Symptomatic during clinical encounter: BSCR-3) Breast implant-related symptoms (effusion, enlargement, mass ulceration) • "i" modified: Randomized trials comparing clinical breast exam versus no >1 year post-implantation screening have not been performed. Rationale for recommending clinical Consultation with multidisciplinary team with experience with implant encounter is to maximize earliest detection of breast cancers and assure related problems including BIA-ALCL ongoing risk assessment. (Also for BSCR-2, BSCR-3) For diagnostic workup of BIA-ALCL, see NCCN Guidelines for T-Cell • "l" modified: Tomosynthesis can decrease call back rates and appears Lymphomas to improve cancer detection but has not been sufficiently studied to Footnotes: determine if it improves disease-specific mortality. (Also for BSCR-2, • "o" is new to the page: Individuals with breast implants have a risk of BSCR-3) developing breast implant-associated anaplastic large cell lymphoma (BIA- BSCR-2 ALCL) (Average 8–10 years after implantation). Majority of cases have been Screening/Follow-up: seen in textured implants. • 1st sub-bullet under Clinical encounter modified: to begin when identified BSCR-5 as being at increased risk but not prior to age 21 y Diagnostic Evaluation: • 2nd sub-bullet modified: Referral to genetic counselingor similarly trained • +Ultrasound was added to Diagnostic mammogram provider, if not already done • 3rd column, significantly modified. • 1st sub-bullet under Annual screening modified: to begin 10 years prior to Work-up: the youngest family member with breast cancer but not prior to age 30 y • Revised: Follow-up After Core Needle Biopsy (See BSCR-8) Continued Version 1.2019, 05/17/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. UPDATES NCCN Guidelines Index NCCN Guidelines Version 1.2019 Table of Contents Breast Cancer Screening and Diagnosis Discussion Updates in Version 1.2019 of the NCCN Guidelines for Breast Cancer Screening and Diagnosis from Version
Load more

Recommended publications
  • EARLY DETECTION Breast Health Awareness and Clinical Breast Exam
    EARLY DETECTION Breast Health Awareness and Clinical Breast Exam Knowledge Summary EARLY DETECTION Breast Health Awareness and Clinical Breast Exam INTRODUCTION KEY SUMMARY Early diagnosis of breast cancer begins with the establish- Early detection programs ment of programs to improve early detection of symptomatic ¬ Early diagnosis of breast cancer can improve survival, lower women, or women with breast lumps that patients and their morbidity and reduces the cost of care when followed by a providers can feel. Early recognition of symptoms and accu- prompt diagnosis and effective treatment. rate diagnosis of breast cancer can result in cancers being diagnosed at earlier stages when treatment is more feasible, ¬ An effective early diagnosis program includes: affordable and effective. This requires that health systems √ Breast health awareness education. have trained frontline personnel who are able to recognize the √ Reducing barriers to accessing care. signs and symptoms of breast abnormalities for both benign √ Clinical breast exam (CBE) performed by primary care breast issues as well as cancers, perform clinical breast exam providers. (CBE) and know the proper referral protocol when diagnostic √ Timely diagnosis for all women found to have abnormal workup is warranted. Women who can identify breast abnor- findings and timely treatment for all women proven by malities, who have timely access to health clinical evaluation, tissue diagnosis to have breast cancer. diagnosis and treatment and who are empowered to seek this √ If supported by evidence, a quality screening mammogra- care are more likely to be diagnosed at an earlier stage (see phy program performed in a cost-effective, resource-sus- Planning: Improving Access to Breast Cancer Care).
    [Show full text]
  • Breast Scintimammography
    CLINICAL MEDICAL POLICY Policy Name: Breast Scintimammography Policy Number: MP-105-MD-PA Responsible Department(s): Medical Management Provider Notice Date: 11/23/2020 Issue Date: 11/23/2020 Effective Date: 12/21/2020 Next Annual Review: 10/2021 Revision Date: 09/16/2020 Products: Gateway Health℠ Medicaid Application: All participating hospitals and providers Page Number(s): 1 of 5 DISCLAIMER Gateway Health℠ (Gateway) medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions. POLICY STATEMENT Gateway Health℠ does not provide coverage in the Company’s Medicaid products for breast scintimammography. The service is considered experimental and investigational in all applications, including but not limited to use as an adjunct to mammography or in staging the axillary lymph nodes. This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person’s unique clinical circumstances warrant individual consideration, based upon review of applicable medical records. (Current applicable Pennsylvania HealthChoices Agreement Section V. Program Requirements, B. Prior Authorization of Services, 1. General Prior Authorization Requirements.) Policy No. MP-105-MD-PA Page 1 of 5 DEFINITIONS Prior Authorization Review Panel – A panel of representatives from within the Pennsylvania Department of Human Services who have been assigned organizational responsibility for the review, approval and denial of all PH-MCO Prior Authorization policies and procedures. Scintimammography A noninvasive supplemental diagnostic testing technology that requires the use of radiopharmaceuticals in order to detect tissues within the breast that accumulate higher levels of radioactive tracer that emit gamma radiation.
    [Show full text]
  • Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary
    Primary Screening for Breast Cancer With Conventional Mammography: Clinical Summary Population Women aged 40 to 49 y Women aged 50 to 74 y Women aged ≥75 y The decision to start screening should be No recommendation. Recommendation Screen every 2 years. an individual one. Grade: I statement Grade: B Grade: C (insufficient evidence) These recommendations apply to asymptomatic women aged ≥40 y who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation Risk Assessment (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Increasing age is the most important risk factor for most women. Conventional digital mammography has essentially replaced film mammography as the primary method for breast cancer screening Screening Tests in the United States. Conventional digital screening mammography has about the same diagnostic accuracy as film overall, although digital screening seems to have comparatively higher sensitivity but the same or lower specificity in women age <50 y. For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during Starting and ages 50 to 74 y. While screening mammography in women aged 40 to 49 y may reduce the risk for breast cancer death, the Stopping Ages number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. The balance of benefits and harms is likely to improve as women move from their early to late 40s.
    [Show full text]
  • Biopsies of the Breast
    American Cancer Society After the procedure is complete, pressure will be applied to the needle site to help stop any bleeding and a bandage will be applied (usually an adhesive Guidelines strip). The procedure takes approximately 30 minutes. Regarding Breast Health Core Needle • Breast Self-Exam (BSE) – More recently the Your Results focus of BSE has been moving from the monthly Your specimens will be delivered to a pathologist who routine self-exam to becoming more self-aware Biopsy will examine them under a microscope. The findings of your breast changes and seeking help if any will be reported to your healthcare provider who will, in abnormalities are noticed. BSE represents a turn, forward the results on to you. structured way in which the breasts can be examined effectively. You should know how your Your Questions breasts normally feel and look. We realize this is a stressful time for you. As our patient, Beginning in their 20’s, women should learn the we want you to be as confident and informed about benefits of BSE. You can be instructed on the your healthcare as you can be. We hope this brochure proper techniques of BSE at the time of your has been informative for you. Please feel free to ask us routine health examination. You should also know any questions you may have. that there are limitations to BSE. Report any breast changes that you notice to your healthcare provider immediately. • Clinical Breast Exam – Women between the Risks ages of 20 and 30 should have a breast exam by a • There is a slight chance of developing bleeding healthcare provider every three years.
    [Show full text]
  • Early Detection and Screening for Breast Cancer
    Seminars in Oncology Nursing, Vol 33, No 2 (May), 2017: pp 141-155 141 EARLY DETECTION AND SCREENING FOR BREAST CANCER CATHY COLEMAN OBJECTIVE: To review the history, current status, and future trends related to breast cancer screening. DATA SOURCES: Peer-reviewed articles, web sites, and textbooks. CONCLUSION: Breast cancer remains a complex, heterogeneous disease. Serial screening with mammography is the most effective method to detect early stage disease and decrease mortality. Although politics and economics may inhibit organized mammography screening programs in many countries, the judi- cious use of proficient clinical and self-breast examination can also identify small tumors leading to reduced morbidity. IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses have exciting oppor- tunities to lead, facilitate, and advocate for delivery of high-quality screening services targeting individuals and communities. A practical approach is needed to translate the complexities and controversies surrounding breast cancer screen- ing into improved care outcomes. KEY WORDS: breast cancer, screening, early stage, quality, breast centers, advocacy. he future is hopeful for the public, pro- fessionals, and interdisciplinary teams as multifaceted progress continues to reveal new insights in carcinogenesis, ge- Cathy Coleman, DNP, MSN, PHN, OCN®, CPHQ, CNL: T nomics, tumor biology, translational research, and Assistant Professor, University of San Francisco School quality improvement from prevention to pallia- of Nursing and Health Professions, San Francisco, CA. tion and survivorship for cancer care.1-8 Oncology Address correspondence to Cathy Coleman, DNP, nurses are on the front line of care delivery across MSN, PHN, OCN®, CPHQ, CNL, University of San settings; they also assert a strong leadership voice Francisco School of Nursing and Health Professions, 2130 Fulton Street, San Francisco, CA 94117.
    [Show full text]
  • State of Science Breast Cancer Fact Sheet
    Patient Version Breast Cancer Fact Sheet About Breast Cancer Breast cancer can start in any area of the breast. In the US, breast cancer is the most common cancer (after skin cancer) and the second-leading cause of cancer death (after lung cancer) in women. Risk Factors Risk factors for breast cancer that you cannot change Lifestyle-related risk factors for breast cancer include: • Drinking alcohol Being born female • Being overweight or obese, especially after menopause This is the main risk factor for breast cancer. But men can get breast cancer, too. • Not being physically active Getting older • Getting hormone therapy after menopause with As a person gets older, their risk of breast cancer estrogen and progesterone therapy goes up. Most breast cancers are found in women • Starting menstruation early or having late menopause age 55 or older. • Never having children or having first live birth after Personal or family history age 30 A woman who has had breast cancer in the past or has a • Using certain types of birth control close blood relative who has had breast cancer (mother, • Having a history of non-cancerous breast conditions father, sister, brother, daughter) has a higher risk of getting it. Having more than one close blood relative increases the risk even more. It’s important to know that Prevention most women with breast cancer don’t have a close blood There is no sure way to prevent breast cancer, and relative with the disease. some risk factors can’t be changed, such as being born female, age, race, and personal or family history of the Inheriting gene changes disease.
    [Show full text]
  • Stochastic Models for Improving Screening and Surveillance Decisions for Prostate Cancer Care
    Stochastic Models for Improving Screening and Surveillance Decisions for Prostate Cancer Care by Christine Barnett A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Industrial and Operations Engineering) in The University of Michigan 2017 Doctoral Committee: Professor Brian T. Denton, Chair Associate Professor Mariel S. Lavieri Professor Lawrence M. Seiford Assistant Professor Scott A. Tomlins Christine L. Barnett [email protected] ORCID iD: 0000-0002-1465-7623 c Christine L. Barnett 2017 DEDICATION For Jon, Amy, and Kate. ii ACKNOWLEDGEMENTS First, I would like to thank my advisor, Dr. Brian Denton, for his guidance and support over the past five years. I am grateful to have had him as a mentor through this experience, and feel prepared for the next stage in my career thanks to his encouragement and guidance. This work was supported in part by the National Sci- ence Foundation through Grant Number CMMI 0844511 and by the National Science Foundation Graduate Research Fellowship under Grant Number DGE 1256260. I would like to thank my committee members Dr. Mariel Lavieri, Dr. Lawrence Seiford, and Dr. Scott Tomlins for serving on my committee and providing me with career advice and helpful feedback on my research. In addition, I would like to thank our collaborators from Michigan Medicine, Dr. Gregory Auffenberg, Dr. Matthew Davenport, Dr. Jeffrey Montgomery, Dr. James Montie, Dr. Todd Morgan, Dr. Scott Tomlins, and Dr. John Wei for their invaluable clinical perspective and for teaching me about the intricacies of prostate cancer screening and treatment decisions. Finally, I would like to thank my friends and family for their support throughout graduate school.
    [Show full text]
  • Clinical Guidelines for the Management of Breast Cancer West Midlands Expert Advisory Group for Breast Cancer West Midlands Clinical Networks and Clinical Senate
    Clinical Guidelines for the Management of Breast Cancer West Midlands Expert Advisory Group for Breast Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group Agreed Documentation This sheet is to accompany all documentation agreed by the West Midlands Strategic Clinical Network Expert Advisory Groups. This will assist the Clinical Network to endorse the documentation and request implementation. EAG name Breast Cancer Expert Advisory Group Document Clinical guidelines for the management of breast cancer Title Published December 2016 date Document Clinical guidance for the management of Breast cancer to all practitioners, Purpose clinicians and health care professionals providing a service to all patients across the West Midlands Clinical Network. Authors Original Author: Mr Stephen Parker Modified By: Mrs Abigail Tomlins Consultant Breast Surgeon University Hospitals Coventry & Warwickshire NHS Trust References Consultation These guidelines were originally authored by Stephen Parker and Process subsequently modified by Abigail Tomlins for the Coventry, Warwickshire and Worcestershire Breast Group. The West Midlands EAG agreed to adopt these guidelines as the regional network guidelines. The version history reflects changes made by the Coventry, Warwickshire and Worcestershire Breast Group. As the Coventry, Warwickshire and Worcestershire Breast Group update their guidelines, the EAG will discuss whether to adopt the updated version. Review Date December 2019 (must be within three years) Approval Network Clinical Director Signatures: Date: 25/10/2017 \\ims.gov.uk\data\Users\GBEXPVD\EXPHOME25\PGoulding\Data\Desktop\guidelines- 2 for-the-management-of-breast-cancer-v1.doc Version History - Coventry, Warwickshire and Worcestershire Breast Group Version Date Brief Summary of Change 2010v1.0D 12 March 2010 Immediate breast reconstruction criteria Young adult survivors Updated follow-up guidelines.
    [Show full text]
  • What You Should Know About Breast Cancer Screening
    Cancer AnswerLineTM WHAT YOU SHOULD KNOW ABOUT BREAST CANCER SCREENING Women should speak to their health care provider about their risk of breast cancer and whether a screening test is right for them, as well as to review the risks and benefits of screening. The purpose of screening is to find disease early; THE AMERICAN CANCER SOCIETY’S ideally before symptoms appear. Almost all diseases, RECOMMENDATIONS: including cancer, are easier to treat in an earlier • Women between 40 and 44 have the option to stage as opposed to an advanced stage. start screening with a mammogram every year. Women 45 to 54 should get mammograms every While experts may have different opinions regarding • year. when to begin mammography screening and at what frequency, all major U.S. organizations, • Women 55 and older can switch to a mammogram including the American Cancer Society, the every other year, or they can choose to continue National Comprehensive Cancer Network and the yearly mammograms. Screening should continue U.S. Preventive Services Task Force continue to as long as a woman is in good health and is recommend regular screening mammography to expected to live 10 more years or longer. reduce breast cancer mortality. Breast cancer • All women should understand what to expect mortality rates have continued to decrease in the when getting a mammogram for breast cancer United States due to advances in screening and screening—what the test can and cannot do. treatment over the last 20 years. These recommendations apply to asymptomatic Breast cancer screening is broken down into women aged 40 years or older who do not have different classifications based the patient’s age, level preexisting breast cancer or a previously diagnosed of risk (how likely they are to get breast cancer), and high-risk breast lesion and who are not at high risk strength of the recommendation.
    [Show full text]
  • Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline Or High-Risk Lesions
    - Official Statement - Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline or High-Risk Lesions Purpose To outline the management approach for borderline and high risk lesions identified on image-guided breast biopsy. Associated ASBrS Guidelines or Quality Measures 1. Image-Guided Percutaneous Biopsy of Palpable and Nonpalpable Breast Lesions 2. Performance and Practice Guidelines for Stereotactic Breast Procedures 3. Concordance Assessment Following Image-Guided Breast Biopsy Methods Literature review inclusive of recent randomized controlled trials evaluating the management of various borderline and high-risk lesions (including atypical hyperplasia, lobular neoplasia, papillary lesions, radial scars and complex sclerosing lesions, fibroepithelial lesions, mucocele-like lesions, spindle cell lesions, and pseudoangiomatous stromal hyperplasia [PASH]) identified on image-guided breast biopsies. This is not a complete systematic review but a comprehensive review of the modern literature on this subject. The ASBS Research Committee developed a consensus document which the ASBS Board of Directors reviewed and approved. Summary of Data Reviewed Percutaneous core needle biopsy (CNB) is the preferred, initial, minimally invasive diagnostic procedure for nonpalpable breast lesions or palpable breast masses.1 Concordance assessment of the histologic, imaging, and clinical findings determines further management. Discordance refers to the situation in which a breast CNB demonstrates benign histology, while the clinical or imaging findings are suspicious for malignancy. If there is discordance between imaging and pathology, histological evaluation is still needed. This can be accomplished either by repeat CNB, perhaps with consideration of larger gauge or vacuum- assisted device, or surgical excision.2-5 Some nonmalignant CNB findings are considered “borderline” because of their potential association with malignancy.
    [Show full text]
  • 5. Effectiveness of Breast Cancer Screening
    5. EFFECTIVENESS OF BREAST CANCER SCREENING This section considers measures of screening Nevertheless, the performance of a screening quality and major beneficial and harmful programme should be monitored to identify and outcomes. Beneficial outcomes include reduc- remedy shortcomings before enough time has tions in deaths from breast cancer and in elapsed to enable observation of mortality effects. advanced-stage disease, and the main example of a harmful outcome is overdiagnosis of breast (a) Screening standards cancer. The absolute reduction in breast cancer The randomized trials performed during mortality achieved by a particular screening the past 30 years have enabled the suggestion programme is the most crucial indicator of of several indicators of quality assurance for a programme’s effectiveness. This may vary screening services (Day et al., 1989; Tabár et according to the risk of breast cancer death in al., 1992; Feig, 2007; Perry et al., 2008; Wilson the target population, the rate of participation & Liston, 2011), including screening participa- in screening programmes, and the time scale tion rates, rates of recall for assessment, rates observed (Duffy et al., 2013). The technical quality of percutaneous and surgical biopsy, and breast of the screening, in both radiographic and radio- cancer detection rates. Detection rates are often logical terms, also has an impact on breast cancer classified by invasive/in situ status, tumour size, mortality. The observational analysis of breast lymph-node status, and histological grade. cancer mortality and of a screening programme’s Table 5.1 and Table 5.2 show selected quality performance may be assessed against several standards developed in England by the National process indicators.
    [Show full text]
  • Breast Imaging Faqs
    Breast Imaging Frequently Asked Questions Update 2021 The following Q&As address Medicare guidelines on the reporting of breast imaging procedures. Private payer guidelines may vary from Medicare guidelines and from payer to payer; therefore, please be sure to check with your private payers on their specific breast imaging guidelines. Q: What differentiates a diagnostic from a screening mammography procedure? Medicare’s definitions of screening and diagnostic mammography, as noted in the Centers for Medicare and Medicaid’s (CMS’) National Coverage Determination database, and the American College of Radiology’s (ACR’s) definitions, as stated in the ACR Practice Parameter of Screening and Diagnostic Mammography, are provided as a means of differentiating diagnostic from screening mammography procedures. Although Medicare’s definitions are consistent with those from the ACR, the ACR's definitions of screening and diagnostic mammography offer additional insight into what may be included in these procedures. Please go to the CMS and ACR Web site links noted below for more in- depth information about these studies. Medicare Definitions (per the CMS National Coverage Determination for Mammograms 220.4) “A diagnostic mammogram is a radiologic procedure furnished to a man or woman with signs and symptoms of breast disease, or a personal history of breast cancer, or a personal history of biopsy - proven benign breast disease, and includes a physician's interpretation of the results of the procedure.” “A screening mammogram is a radiologic procedure furnished to a woman without signs or symptoms of breast disease, for the purpose of early detection of breast cancer, and includes a physician’s interpretation of the results of the procedure.
    [Show full text]